Testing Skin Allergy Safety of Cancer Biotherapy Drugs in Adults
Finds safe, non-irritating doses of cancer biotherapy for allergy skin tests.
Key facts
- Who runs it
- Centre Hospitalier Universitaire D'Angers
- Where
- Angers, FranceSee the site
- Trial code
- Registry title
- ETCABio - Evaluation of Skin Tests in Biotherapy Allergies
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 140 people, planned
- Started
- 17 Jun 2026
- Expected to end
- 20 May 2027
- Type of study
- Interventional
- Record updated
- 19 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are treated with one of seven biotherapy drugs and have had at least two injections without a suspected allergic reaction. It tests skin tests for drug allergy.
- Age
- 18 years or older
- Sex
- All sexes can join
- Earlier treatment
- Must be treated with Atezolizumab, Nivolumab, Obinutuzumab, Durvalumab, Pembrolizumab, Daratumumab or Cemiplimab. Must have had at least two injections without suspected allergic side effects. Any oral or IV corticosteroids and H1 antihistamines must be stoppable at least one week before the tests.
Main reasons for not taking part
- Skin problems such as psoriasis or eczema that could disturb the skin test results
- Poor understanding of the French language
- Pregnancy or breastfeeding
- Persons in detention by judicial or administrative decision
- Persons under a legal protection measure
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age ≥ 18 years
- Patient treated with one of the biotherapies under study (Atezolizumab, Nivolumab, Obinutuzumab, Durvalumab, Pembrolizumab, Daratumumab, Cemiplimab) and who has received at least two injections of the biotherapy without suspected allergic side effects
- Subjects covered by or having the rights to medical care assurance
- Written informed consent obtained from subject
- If applicable, treatment with corticosteroids and H1 antihistamines by systemic route (IV or oral) which may be discontinued at least one week before performing the tests (Inhaled corticosteroids are allowed)
Who cannot take part
- Pregnancy, breastfeeding* (For women of childbearing age, the absence of pregnancy will be confirmed by a blood pregnancy test (unless already conducted as part of the care or if pregnancy is ruled out)
- Presence of local or diffuse dermatological lesions (e.g., psoriasis, eczema, ...) that could interfere with the interpretation of skin tests
- Poor understanding of the French language
- Persons in detention by judicial or administrative decision
- Person admitted to a health or social establishment for purposes other than research
- Person subject to a legal protection measure
Where in France
- Centre Hospitalier Universitaire D'AngersAngers, FranceTaking people
About the trial
What the trial wants to find out
The primary objective is to determine, in non-allergic patients treated with biotherapy, the maximum non-irritant concentration of the biotherapy that can be used in allergologic skin tests (prick tests and intradermal tests) for patients suspected of hypersensitivity to the said biotherapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- ETCABio - Evaluation of Skin Tests in Biotherapy Allergies
- Plain-language title
- Testing Skin Allergy Safety of Cancer Biotherapy Drugs in AdultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 19 March 2026